Table 1.
Clinical characteristics of AML patients
| Items | AML patients (N = 221) |
|---|---|
| Age (years), mean ± SD | 52.1 ± 14.9 |
| Gender, No. (%) | |
| Female | 85 (38.5) |
| Male | 136 (61.5) |
| FAB classification, No. (%) | |
| M2 | 79 (35.7) |
| M4 | 65 (29.4) |
| M5 | 66 (29.9) |
| M6 | 11 (5.0) |
| Cytogenetics, No. (%) | |
| NK | 113 (51.1) |
| CK | 25 (11.3) |
| inv(16) or t(16;16) | 17 (7.7) |
| t(8;21) | 10 (4.5) |
| +8 | 7 (3.2) |
| −7 or 7q‐ | 7 (3.2) |
| t(9;11) | 7 (3.2) |
| 11q23 | 6 (2.7) |
| t(9;22) | 4 (1.8) |
| inv(3) or t(3;3) | 2 (0.9) |
| −5 or 5q‐ | 1 (0.5) |
| t(6;9) | 1 (0.5) |
| Others (non‐defined) | 21 (9.5) |
| MK, No. (%) | 19 (8.6) |
| Molecular genetics mutation, No. (%) | |
| FLT3‐ITD mutation | 48 (21.7) |
| Isolated biallelic CEBPA mutation | 22 (10.0) |
| NPMI mutation | 78 (35.3) |
| Risk stratification, No. (%) | |
| Favorable‐risk | 58 (26.3) |
| Intermediate‐risk | 88 (39.8) |
| Poor‐risk | 75 (33.9) |
| WBC (×109/L), median (IQR) | 17.0 (8.5‐29.2) |
| Induction therapy regimens, No. (%) | |
| Daunorubicin + cytarabine | 96 (43.4) |
| Idarubicin + cytarabine | 85 (38.5) |
| Anthracenedione mitoxantrone + cytarabine | 40 (18.1) |
Abbreviations: AML, acute myeloid leukemia; CEBPA, CCAAT/enhancer‐binding protein α; CK, complex karyotype; FAB classification, French‐American‐Britain classification; FLT3‐ITD, internal tandem duplications in the FMS‐like tyrosine kinase 3; IQR, interquartile range; MK, monosomal karyotype; NK, normal karyotype; NPM1, nucleophosmin 1; SD, standard deviation; WBC, white blood cell.